Raymond James Financial’s Neurogene NGNE Stock Holding History

Raymond James Financial’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$120	–	6100
2025 Q2	$120	Buy	+8	New	+$126	﹤0.01%	6826

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial's NGNE Position: Q3 2025 in Review

Raymond James Financial sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 8 shares — an estimated $120 sold.

Raymond James Financial first reported a position in NGNE in Q2 2025 and held it in 1 quarter. The position peaked at $120 in Q2 2025. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

Raymond James Financial reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 8 Neurogene shares in Q3 2025, an estimated $120.
Raymond James Financial first reported a position in Neurogene in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Neurogene position peaked at $120 in Q2 2025.
88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.